



**Figure 1. Cumulative incidence of TB by 54 weeks, by treatment group and trial**



Number at risk (TB endpoints)

TB-CHAMP Levofloxacin	451	(1)	425	(0)	412	(0)	368	(1)	339	(3)
TB-CHAMP Placebo	465	(3)	441	(7)	414	(0)	379	(0)	357	(2)
VQUIN Levofloxacin	1023	(0)	1020	(0)	1019	(1)	1018	(2)	1014	(0)
VQUIN Placebo	1018	(2)	1014	(2)	1011	(4)	1004	(1)	1003	(0)



Excluded 6 participants in TB-CHAMP who were late screening failure with TB at baseline.

The confidence intervals of the Kaplan-Meier cumulative incidence estimates are presented in Supplemental Appendix Table S7.13.